RBD5044

DRUG3 trials

Sponsors

Suzhou Ribo Life Science Co. Ltd., Ribocure Pharmaceuticals AB, Ribotek Biopharmaceuticals (Shandong) Co., Ltd

Conditions

DyslipidemiasHealth VolunteerHypertriglyceridemia

Phase 1

A Single and Multiple Ascending Doses Study to Evaluate the Safety and Pharmacokinetics of RBD5044

CompletedNCT05539651

Suzhou Ribo Life Science Co. Ltd.Health Volunteer

Start: 2022-11-10End: 2024-10-30Updated: 2024-12-04

Phase 2

Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients With Mixed Dyslipidemia

RecruitingNCT06797401

Ribocure Pharmaceuticals ABDyslipidemias

Start: 2025-01-28End: 2027-09-30Target: 120Updated: 2026-09-10

RBD5044 in Chinese Participants With Hypertriglyceridemia

Active, not recruitingNCT07587788

Ribotek Biopharmaceuticals (Shandong) Co., LtdHypertriglyceridemia

Start: 2026-02-28End: 2027-03-01Target: 40Updated: 2026-08-24